Test of a new antibody drug for advanced cancers
Part of Cancer clinical trials.
This trial tests an experimental antibody drug called SIG001 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your cancer is advanced (has spread) or has come back, and you've tried standard treatments that didn't work or you can't have them.
- You have at least one tumor that can be measured on a scan.
- You are able to care for yourself and are not bedridden.
- Your heart, liver, kidneys, and blood counts are working well enough (you'll get tests to check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This trial tests a new drug (SI-B036) for people with advanced urological tumors or other solid tumors that have spread. The goal is to see if the drug is safe and effective, and it might help shrink tumors or slow their growth.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
Hear when a new Neoplams trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.